Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A
RegulatoryapprovedFREHEMGO®Positive
AI Analysis
Summary
Novo's FREHEMGO® (denecimig), a factor VIIIa mimetic for haemophilia A, received a positive CHMP recommendation for EU marketing authorisation. The drug offers flexible dosing options including monthly, bi-weekly, and weekly administration via pre-filled pen.
Outcome Details
CHMP recommends EU marketing authorisation; EMA adopted positive opinion
Importance:9/10
Sentiment:
0.95
EMA approvalhaemophilia Afactor VIII mimeticregulatory milestonemonthly dosing
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 17, 2026 2:14 PM